IDEX (NYSE:IEX) updated its FY 2021 earnings guidance on Tuesday. The company provided EPS guidance of 6.050-6.200 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.880. The company issued revenue guidance of -.IDEX also updated its Q2 2021 guidance to 1.600-1.630 EPS.
Several brokerages recently issued reports on IEX. Zacks Investment Research upgraded IDEX from a hold rating to a buy rating and set a $199.00 price target for the company in a research note on Friday, February 5th. Morgan Stanley upped their target price on IDEX from $230.00 to $250.00 and gave the stock an overweight rating in a research note on Thursday, April 29th. DA Davidson upped their target price on IDEX from $190.00 to $205.00 and gave the stock a neutral rating in a research note on Thursday, April 29th. They noted that the move was a valuation call. Royal Bank of Canada upped their target price on IDEX from $232.00 to $247.00 and gave the stock an outperform rating in a research note on Thursday, April 29th. Finally, Rosenblatt Securities increased their price objective on IDEX from $225.00 to $255.00 and gave the company a buy rating in a report on Monday. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. IDEX currently has an average rating of Buy and a consensus price target of $223.44.
NYSE IEX opened at $223.50 on Tuesday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 2.97 and a current ratio of 3.71. The company has a market capitalization of $16.97 billion, a P/E ratio of 45.71, a P/E/G ratio of 3.53 and a beta of 1.08. The company has a fifty day moving average of $213.57 and a 200-day moving average of $198.87. IDEX has a 52-week low of $141.86 and a 52-week high of $235.76.
IDEX (NYSE:IEX) last announced its quarterly earnings results on Monday, April 26th. The industrial products company reported $1.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.41 by $0.10. The company had revenue of $652.04 million for the quarter, compared to analysts' expectations of $634.96 million. IDEX had a net margin of 15.94% and a return on equity of 17.21%. IDEX's quarterly revenue was up 9.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.33 earnings per share. As a group, analysts forecast that IDEX will post 5.15 EPS for the current fiscal year.
In other IDEX news, SVP Denise R. Cade sold 3,750 shares of the company's stock in a transaction that occurred on Tuesday, February 16th. The shares were sold at an average price of $200.11, for a total transaction of $750,412.50. 1.10% of the stock is owned by corporate insiders.
IDEX Company Profile
IDEX Corporation, together with its subsidiaries, operates as an applied solutions company worldwide. The company operates through three segments: Fluid & Metering Technologies (FMT), Health & Science Technologies (HST), and Fire & Safety/Diversified Products (FSDP). The FMT segment designs, produces, and distributes positive displacement pumps, small volume provers, flow meters, injectors, and other fluid-handling pump modules and systems, as well as offers flow monitoring and other services for the food, chemical, general industrial, water and wastewater, agricultural, and energy industries.
Recommended Story: What defines an oversold asset?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured Article: How to Trade Using Analysts Ratings7 Healthcare Stocks Delivering Innovation in 2021
We all knew that traditional healthcare services were disrupted in 2020. The patient-doctor relationship went virtual. In the early months of the pandemic, many people in need of elective surgeries simply did not have that option available to them. And even local pharmacies took on a new e-commerce role as curbside pickup or home delivery of prescription medication became the norm.
Not surprisingly healthcare stocks were battered last year. Overall, the sector was down 11%, far below the S&P 500 Index that climbed over 15%.
However, the market is always forward-looking with a particular eye towards innovation. The healthcare sector has many companies that are developing innovative approaches in areas such as gene editing. And other companies are in late-stage trials for drugs that can deliver breakthrough results for conditions that continue to plague our world.
That’s the focus of this presentation. We’ve identified 7 healthcare stocks that are delivering innovative ideas that will help deliver better patient outcomes. And in some cases will revolutionize medicine altogether. These are also the stocks that analysts have their eye on.
View the "7 Healthcare Stocks Delivering Innovation in 2021"